Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

D. Solomon, Scott; J.V. McMurray, John; Claggett, Brian; A. de Boer, Rudolf; L. DeMets, David; F. Hernandez, Adrian; E. Inzucchi, Silvio; Kosiborod, Mikhail; S.P. Lam, Carolyn; A. Martínez, Felipe; J. Shah, Sanjiv; S. Desai, Akshay; S. Jhund, Pardeep; Bělohlávek, Jan; Chiang, Chern‐En; Jan Willem Borleffs, C.; Comín‐Colet, Josep; Dobreanu, Dan; Dróżdż, Jarosław; C. Fang, James; A. Alcocer‐Gamba, Marco; Al Habeeb, Waleed; Han, Yaling; Walter Cabrera Honorio, Jose; Janssens, Stefan; Katova, Tzvetana; Kitakaze, Masafumi; Merkely, Béla; O’Meara, Eileen; Francisco Kerr Saraiva, José; Н. Терещенко, С.; Thierer, Jorge; Vaduganathan, Muthiah; Vardeny, Orly; Verma, Subodh; Pham, Vinh; Wilderäng, Ulrica; Zaozerska, Natalia; Bachus, Erasmus; Lindholm, Daniel; Petersson, Magnus; Maria Langkilde, Anna

doi:10.1056/nejmoa2206286

Public

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Published in New England Journal of Medicine • Aug 27, 2022

Authors:

Scott D. Solomon

John J.V. McMurray

Brian Claggett

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a hig...

Subject

Ejection fraction

Dapagliflozin

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!